실시간
FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownBioPharma DiveInnovation alone is no longer enough in biopharmaBioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalabilityRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical developmentFierceBiotechManaging complexity across biopharma modalitieseLifeA macroevolution-inspired approach to reveal novel antibiotic resistance mechanismseLifeA comprehensive mechanosensory connectome reveals a somatotopically organized neural circuit architecture controlling stimulus-aimed grooming of the <i>Drosophila</i> headNINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxEndpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
Endpoints News 2026년 1월 21일

J&J praises new FDA guidance to speed development of multiple myeloma drugs

J&J praises new FDA guidance to speed development of multiple myeloma drugs

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.